Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule (CMS-1850-F)
On November 4, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that updates Medicare payment policies and rates for hospital outpatient and Ambulatory Surgical Center (ASC) services under the Hospital Outpatient Prospective Payment System (OPPS) and ASC Payment System for calendar year (CY) 2027. CMS is publishing this final rule consistent with statutory requirements to review and update Medicare payment rates for hospital outpatient departments and ASCs annually. This fact sheet discusses the final rule’s major provisions.
These payment updates affect approximately 3,500 hospitals and approximately 6,400 ASCs. In addition to finalizing the payment rates, this year’s rule includes updates to the methodology used to calculate the Overall Hospital Quality Star Rating to emphasize the Safety of Care measure group in hospitals’ star ratings. CMS is also finalizing changes to the Hospital Outpatient Quality Reporting (OQR) and ASC Quality Reporting (ASCQR) programs to further meaningful measurement and reporting for outpatient quality of care.
Updates to OPPS and ASC Payment Rates
In accordance with statutory requirements, CMS is finalizing an update to the OPPS payment rates for hospitals that meet applicable quality reporting requirements by 2.3%. This update is based on the projected hospital market basket percentage increase of 3.2%, reduced by a 0.9 percentage point productivity adjustment.
For CY 2027, using the hospital market basket update, CMS is finalizing an update factor to the ASC rates of 2.3%. The update applies to ASCs meeting relevant quality reporting requirements. This update is based on the IPPS market basket percentage increase of 3.2%, reduced by 0.9 percentage point for the productivity adjustment.
Expanding the Method to Control Unnecessary Increases in the Volume of Outpatient Services
In the CY 2019 OPPS/ASC final rule, CMS adopted a method to control unnecessary increases in the volume of clinic visit services furnished in excepted off-campus provider-based departments (PBDs). This method prevents Medicare and beneficiaries from paying significantly more in the excepted off-campus PBD setting than in the physician office setting for some services. In the CY 2026 OPPS/ASC final rule, CMS finalized a policy expansion to include drug administration services furnished in excepted off-campus PBDs. For CY 2027, CMS is finalizing a policy to apply this volume control method to imaging without contrast services, which include certain bone density scans, x-rays, ultrasounds, CT scans and MRIs, furnished in excepted off-campus PBDs. Specifically, CMS is using the agency’s authority under section 1833(t)(2)(F) of the Social Security Act to apply the Physician Fee Schedule equivalent payment rate for any HCPCS codes assigned to the imaging without contrast ambulatory payment classifications (APCs) when provided at an off-campus PBD excepted from section 603 of the Bipartisan Budget Act of 2015. As with the existing volume control method for off-campus clinic visits and drug administration services, CMS is exempting rural Sole Community Hospitals from this policy.
For CY 2027, we estimate this provision would reduce Medicare Part B expenditures by approximately $260 million in the first year, including approximately $190 million in Part B savings and approximately $70 million in reduced beneficiary premiums. In addition, beneficiary cost-sharing obligations are estimated to decrease by approximately $70 million in the first year. This policy helps ensure that beneficiaries are not subject to higher premiums and cost sharing based solely on the site at which care is furnished.
Reduced Payments for 340B-Acquired Drugs Based on the Medicare OPPS Drugs Acquisition Cost Survey
Section 1833(t)(14)(D)(ii) of the Social Security Act requires the Secretary to periodically conduct hospital drug acquisition cost surveys for specified covered outpatient drugs and use this information to help set the payment rates for such drugs. Additionally, on April 18, 2025, President Trump signed Executive Order (E.O.) 14273, “Lowering Drug Prices by Once Again Putting Americans First.” Section 5 of the E.O., “Appropriately Accounting for Acquisition Costs of Drugs in Medicare” directs the Secretary of HHS to publish in the Federal Register a plan to conduct a survey under section 1833(t)(14)(D)(ii) of the Social Security Act to determine the hospital acquisition cost for covered outpatient drugs at hospital outpatient departments.
Accordingly, from Jan. 1, 2026, through April 7, 2026, we conducted a survey of the acquisition costs for each separately payable drug acquired by all hospitals paid under the OPPS. The survey revealed significant disparities between hospital acquisition costs for drugs acquired through the 340B program and those drugs acquired outside of the 340B program. In some instances, the survey revealed that the beneficiary cost-sharing amount, typically 20% of the total payment amount, was greater than the total price that the hospital paid for the drug.
Taking the survey’s results into account to more accurately align Medicare payments with hospital drug acquisition costs, we are finalizing for CY 2027 to pay for 340B-acquired drugs at the drug’s Average Sales Price (ASP) minus 28%.
This payment policy is estimated to reduce Original Medicare drug payment by $4.35 billion and beneficiary drug payments by $1.1 billion in the first year. Statute requires that this policy be implemented in a budget neutral manner, so this policy will increase OPPS payments for non-drug services by an equivalent amount.
The individual beneficiary who receives a qualifying drug in the hospital outpatient department is expected to save an average of $900 in drug costs in CY 2027.
CY 2027 Prospective Adjustment to Payments for Non-Drug Items and Services to Offset the Increased Payments for Non-Drug Items and Services Made in CY 2018 Through CY 2022 as a Result of the Prior 340B Payment Policy
The November 2023 340B Remedy final rule (88 FR 77150) finalized changes to the calculation of the OPPS conversion factor applicable to non-drug items and services beginning in CY 2026. Specifically, effective Jan. 1, 2026, the rule codified a 0.5% reduction in the OPPS conversion factor applicable to non-drug items and services, excluding hospitals that enrolled in Medicare after Jan. 1, 2018. This reduction would remain in effect until the estimated aggregate payment reduction reached the $7.8 billion of increased non-drug items and services payments made from CY 2018 through CY 2022.
This prospective offset aimed to balance the goal of restoring hospitals to their financial position had the original 340B policy never existed with avoiding burdening them with an immediate single year recovery. After subsequent reconsideration of balancing these two goals, CMS has determined a shorter timeframe to be more appropriate, consistent with our discussion in the CY 2026 OPPS/ASC final rule with comment period. During CY 2026 rulemaking, we proposed, but did not finalize, a 2% reduction in the OPPS conversion factor for CY 2026. Although we did not finalize an increase to the 0.5% reduction for CY 2026, we indicated in the CY 2026 final rule that we anticipated delaying an increase for only a single year and that commenters should expect an increase greater than 0.5% in CY 2027. Consequently, after consideration of the public comments received on the proposed rule, CMS is finalizing a revision to the annual offset percentage for non-drug items and services from 0.5% to 2% effective CY 2027, excluding hospitals that enrolled in Medicare after Jan. 1, 2018. This 2% reduction will remain in effect until the estimated payment reduction reaches $7.8 billion, which CMS estimates will occur in CY 2031.
Eliminating the Inpatient Only (IPO) List
To give beneficiaries more choices on where to obtain care with the potential for lower out-of-pocket expenses, CMS is continuing to phase out the IPO list over a three-year period. For this second year of the phase out, CMS is finalizing its proposal to remove 637 services from the following clinical families: auditory, digestive, endocrine, female genital, hemic and lymphatic systems, integumentary, male genital, maternity care and delivery, mediastinum and diaphragm, respiratory, and urinary. CMS believes that the evolving nature of medical practice allows more procedures to be performed on an outpatient basis with a shorter recovery time. This will allow for these services to be paid by Medicare in the hospital outpatient setting when determined to be clinically appropriate, giving physicians greater flexibility in determining the most appropriate site of service.
Adjustment to Cost-of-Living in Alaska and Hawaii
Hospitals located in Alaska and Hawaii face unique geographical circumstances, including dependency on outside goods and components, remote locations and transportation challenges, and other factors inherent to providing healthcare in these noncontiguous states. While higher labor-related costs for these two states are considered under the OPPS through the IPPS hospital wage index, the nonlabor portion of OPPS payment does not currently address higher nonlabor costs in these states as in the IPPS through a Cost-of-Living-Adjustment (COLA) policy. To resolve this inconsistency between the IPPS and OPPS, we are applying a COLA to the nonlabor share of outpatient hospital service payments provided in Alaska and Hawaii for CY 2027 and future years based on the IPPS COLA. The finalized policy is budget neutral across the OPPS and is projected to increase payments to hospitals in these states by $66 million in CY 2027.
Intensive Outpatient and Partial Hospitalization Programs
Intensive Outpatient Program (IOP) and Partial Hospitalization Program (PHP) Rate Setting
The CY 2027 OPPS/ASC final rule updates Medicare payment rates for IOP and PHP services furnished in hospital outpatient departments and Community Mental Health Centers (CMHCs). The IOP is a distinct and organized outpatient program of psychiatric services provided for individuals who have an acute mental illness or substance use disorder, consisting of a specified group of behavioral health services paid on a per diem basis for a minimum of nine hours of IOP services per week under the OPPS, or other applicable payment system, when furnished in hospital outpatient departments, CMHCs, Federally Qualified Health Centers (FQHCs), and Rural Health Clinics (RHCs). IOP services may also be furnished in Opioid Treatment Programs (OTPs) for opioid use disorder (OUD). The PHP is an intensive, structured outpatient program provided as an alternative to psychiatric hospitalization, consisting of a specified group of mental health services paid on a per diem basis for a minimum of 20 hours of PHP services per week under the OPPS, based on PHP per diem costs.
Update to IOP and PHP Payment Rates in Hospital Outpatient Departments and CMHCs
CMS is finalizing its proposal to maintain the existing rate structure, with two IOP APCs for each provider type and two PHP APCs for each provider type. For CY 2027, CMS is calculating hospital-based PHP payment rates for three services per day and four or more services per day based on cost per day using OPPS data that includes IOP or PHP and non-IOP or PHP days. CMS believes continuing to use the OPPS data set will allow CMS to capture data from hospital claims that are not identified as IOP or PHP but that include the service codes and intensity required for an IOP or PHP day. CMS calculates CMHC costs based on 40% of the hospital-based PHP and IOP costs.
Payment for Software as a Medical Service (SaMS)
Over the past decade, there have been rapid developments in the use of software-based technologies to diagnose disease and support clinical decision-making in outpatient and physician office settings. To more appropriately refer to these technologies, we are finalizing a change in Medicare terminology for these services from Software as a Service (SaaS) to Software as a Medical Service (SaMS). As CMS is considering these rapidly evolving SaMS, we are finalizing our proposal to assign them to New Technology APCs as an interim step toward a broader payment policy.
SaMS Analyses Performed on Laboratory Tests
We have also seen an increase in the development of subsequent stand-alone algorithmic analyses, which we refer to as “SaMS analyses performed on laboratory tests.” We believe that these services are substantially similar to SaMS already paid for under the OPPS, in part because both services provide algorithmic analyses of data generated by a prior laboratory test. While these secondary analyses are currently paid for under the Medicare Clinical Laboratory Fee Schedule (CLFS) as “clinical diagnostic laboratory tests,” for CY 2027, we are finalizing payment for these services as “other diagnostic tests” under section 1861(s)(3) of the Act for payment under the OPPS. Specifically, we are finalizing payment for a small number of SaMS analyses performed on laboratory tests from the CLFS to the OPPS by assigning the codes to New Technology APCs that align with current CY 2026 CLFS payment rates.
Cross-Program Proposal for the Hospital Outpatient and ASC Quality Reporting Programs
CMS is finalizing the removal of the Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients measure from the Hospital Outpatient and ASC Quality Reporting Programs beginning with the CY 2027 reporting period/CY 2029 payment determination.
Hospital Outpatient Quality Reporting (OQR) Program
The Hospital Outpatient Quality Reporting Program is a pay-for-reporting quality program for hospital outpatient departments that requires hospitals to meet quality reporting requirements or receive a reduction of two percentage points in their annual payment update if these requirements are not met.
In addition to the cross-program measure removal described previously, in the CY 2027 OPPS/ASC final rule, CMS is finalizing updates to the validation of Hospital Outpatient Quality Reporting Program data, including the validation of electronic clinical quality measure (eCQM) measures.
Ambulatory Surgical Center (ASC) Quality Reporting Program
The ASC Quality Reporting Program requires ASCs providing care to people with Medicare to report data on certain measures of clinical quality. These quality measures reflect priorities including safety and readmissions. Ambulatory surgical centers must meet all program requirements to receive their full annual payment rate update.
Apart from the cross-program measure removal described previously, CMS is not finalizing any changes to the ASC Quality Reporting Program.
Rural Emergency Hospital (REH) Quality Reporting Program
Rural Emergency Hospitals (REHs) are a recently established Medicare provider type. A REH must submit quality measure data under the REH Quality Reporting Program, but no payment incentive or financial penalty is associated with the requirement.
CMS did not propose or finalize any updates to the Rural Emergency Hospital Quality Reporting Program in the CY 2027 OPPS/ASC final rule.
AO Deeming Authority for EMTALA
EMTALA requires all Medicare-participating hospitals, including Critical Access Hospitals (CAHs) and REHs, to provide appropriate medical screening examinations, necessary stabilizing treatment to individuals with emergency medical conditions, and appropriate treatment or if necessary, appropriate transfers for individuals presenting to emergency departments that require a higher level of care not available at the originating hospital. CMS is finalizing the allowance of hospital accrediting organizations (AOs) with deeming authority to assess compliance with EMTALA’s administrative requirements under 42 CFR 489.20, including posting required signage, maintaining a central emergency department log, retaining transfer records for five years, and keeping an on-call physician list as part of routine accreditation and reaccreditation surveys. CMS is amending 42 CFR 488.5(a) by adding a new provision requiring AOs to document the procedures used to inspect for EMTALA administrative violations within their existing survey processes. Because more than 80% of hospitals are AO-accredited, integrating this oversight into routine surveys would reduce duplicate state complaint investigations and minimize disruption to hospital operations. Enforcement authority over the substantive patient care protections at 42 CFR 489.24 would remain exclusively with CMS and the Office of Inspector General (OIG). This enforcement authority includes EMTALA complaint investigations conducted by CMS, which are carried out to ensure compliance with the patient care protections set forth under 42 CFR 489.24.
Prior Authorization for Additional Botulinum Toxin Injection Codes
Through routine data analysis, CMS identified that billing for botulinum toxin injection procedures in the hospital outpatient setting increased in volume. CMS researched possible causes for that volume increase but did not find any explanations to justify it. Both data and research showed that such an increase is unnecessary, and further program integrity action was warranted. In the CY 2020 OPPS/ASC final rule with comment period, CMS established a prior authorization process for certain hospital outpatient department services using our authority under section 1833(t)(2)(F) of the Act, which requires the Secretary to develop “a method for controlling unnecessary increases in the volume of covered OPD services.”
CMS continues using prior authorization to reduce unnecessary increases in the volume of OPD services. In the CY 2027 OPPS/ASC final rule, CMS is finalizing a proposal to require prior authorization for eight additional botulinum toxin injection codes. CMS believes prior authorization is an effective mechanism to ensure Medicare beneficiaries receive medically necessary care while protecting the Medicare Trust Fund from unnecessary increases in volume and improper payments.
For more information about Hospital Outpatient PPS, please visit: https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient
###